Prevalence of sarcopenia in patients with COPD through different musculature measurements: An updated meta-analysis and meta-regression

Abstract

AimChronic obstructive pulmonary disease (COPD) patients vary widely in terms of the prevalence of sarcopenia, which is partially attributed to differences in diagnostic criteria and disease severity. There are several different musculature measurements that are used to quantify sarcopenia. This study included published literature for meta-analysis to assess the sarcopenia prevalence in COPD patients and correlate the disease with the clinical characteristics of such patients.MethodsA comprehensive review of the English and Chinese literature on sarcopenia prevalence in COPD patients was conducted using electronic databases such as China National Knowledge Infrastructure (CNKI), Web of Science, Cochrane Library, EMBASE, PubMed, and Wanfang. Two researchers analyzed the studies for Newcastle-Ottawa Scale. The software Stata 11.0 was employed for the analysis of the acquired data. The standard mean differences method was utilized for the estimation and quantification of the effect size. Furthermore, a fixed- or random-effects model was employed for conducting a combined analysis.ResultsIn total, 56 studies were included as per the specific inclusion criteria. The resulting data of the assessed COPD patients in this research indicated a 27% prevalence of sarcopenia. Further analysis of subgroups was executed per disease severity, ethnicity, diagnostic criteria, gender, and age. Per these findings, increased disease severity elevated the prevalence of sarcopenia. The Latin American and Caucasian populations indicated an increased prevalence of sarcopenia. In addition, the prevalence of sarcopenia was related to diagnostic criteria and definition. Male COPD patients had a higher prevalence of sarcopenia than female COPD patients. COPD patients with an average age greater than 65 had a slightly higher prevalence of sarcopenia. COPD patients with comorbid sarcopenia had poorer pulmonary function, activity tolerance, and clinical symptoms than patients with COPD alone.ConclusionSarcopenia prevalence is high (27%) in COPD patients. In addition, these patients had worse pulmonary function and activity tolerance compared to patients without sarcopenia.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=367422, identifier CRD42022367422.

Body composition impacts outcome of bronchoscopic lung volume reduction in patients with severe emphysema: a fully automated CT-based analysis

“…Recent meta-analyses conducted by Sepúlveda‐Loyola et al and He et al reported prevalence rates ranging from 15.5 to 34% in the examined studies. These findings suggest a higher prevalence of sarcopenia in patients at advanced disease stages and its association with poorer pulmonary function and exercise capacity 24 , 25 . Martínez‑Luna et al demonstrated a strong association between low muscle mass and poor spirometry results, particularly in FEV 1 and FVC 26 .…”

20 years of neuromuscular electrical stimulation in COPD

“…Other important factors contribute to heterogeneity of patients. These comprise the ability to tolerate high stimulation intensities, muscle mass, deconditioning and sarcopenia [ 49 ] or cachexia. Still, they are not deeply investigated or reported by the authors, although deserving attention.…”

Risk Factors for Sarcopenia in Thai Patients with Rheumatoid Arthritis

“…All patients who were aged 18 years or older and diagnosed with RA according to the 1987 American College of Rheumatology (ACR) revised criteria [18] or the 2010 ACR/European League Against Rheumatism (EULAR) criteria [19], were consecutively recruited. Patients were excluded if they couldn't stand, walk, or perform handgrip strength by themselves, had overlap syndrome with other rheumatic or autoimmune disorders and vasculitides, had other risk factors for sarcopenia, e.g., chronic obstructive pulmonary disease [5,[20][21][22], end stage liver disease [6], neuromuscular disease, or had a metallic device implanted that might interfere with the body impedance analyzer interpretation. All participants were required to provided their informed consent prior to enrollment.…”